NVS

Novartis AG (NVS) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov^[5], including 57 Phase 3^[1], 58 Phase 2^[2], 30 Phase 1^[3], 14 Phase 4^[4].

Trial NCT05948943^[6] evaluates Alpelisib in Lymphatic Malformations with a target enrollment of 232 participants. Trial NCT05939414^[7] evaluates AAA617 in Oligometastatic Prostate Cancer (OMPC) with a target enrollment of 450 participants. Trial NCT05156281^[8] evaluates Remibrutinib in Relapsing Multiple Sclerosis with a target enrollment of 1011 participants.

No Form 4 insider filings for NVS were recorded at the SEC in the past 30 days^[9].